A Randomized, Multicenter, Double Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects With Resected Esophageal, or Gastroesophageal Junction Cancer

Description

Brief Summary

The primary purpose of this study is to determine whether Nivolumab will improve disease-free survival compared with placebo.

N/A

Diagnosed with Stage II/III carcinoma of the esophagus or gastroesophageal junction
Completed pre-operative chemo radiotherapy followed by surgery
Diagnosed with residual pathologic disease after being surgically rendered free of disease with negative margins following complete resection

Diagnosed with cervical esophageal carcinoma
Diagnosed with Stage IV resectable disease
Did not receive concurrent chemoradiotherapy prior to surgery
Participants who have received a live/attenuated vaccine within 30 days of the first treatment Other protocol defined Inclusion/exclusion criteria could apply

Please contact the trial administrator to learn more about where you can participate in this trial. Please use the contact form on the right side.